ProCE Banner Activity

Realizing the Promise of Targeted Therapies in Cell Signaling: NTRK, ROS1, FGFR, RET

Slideset Download
In this downloadable slideset, Todd M. Bauer, MD, discusses the current data on optimal treatment options for patients with NTRK, ROS1, FGFR, or RET altered tumors.

Released: June 03, 2019

Expiration: June 01, 2020

No longer available for credit.

Share

Faculty

Todd M. Bauer

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Array BioPharma

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Foundation Medicine

Genentech TEXT Only

Loxo Oncology

Merck Oncology

Puma Biotechnology, Inc.

Faculty Disclosure

Primary Author

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee